



Note: the [COVID-19 vaccine information sheets and screening questions](#) must also be utilized when obtaining informed consent.

For all clients:

Individuals 18 years and older who received a first dose of AstraZeneca/COVISHIELD COVID-19 vaccine have a choice to receive either the AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer/BioNTech or Moderna) for the second dose, unless there are contraindications such as an allergy. The National Advisory Committee on Immunization updated their recommendations to support mixing different brands or types of COVID-19 vaccines based on recent studies and expert opinion.

Refer to [CV-19 G0145 – Guidance on Interchanging Brands](#) for dosing intervals

1. Has it been at least 28 days since your first dose of AstraZeneca/COVISHIELD?

Yes- proceed to #2

No- advise the client to return once it has been at least 28 days.

2. Would you like to have AstraZeneca/COVISHIELD or an mRNA vaccine for your second shot?

For clients who select an mRNA COVID-19 vaccine or are undecided:

- a. *Please consider the following information on mixing different brands or types of COVID-19 vaccines in order to provide consent for your immunization today:*
 - i. *Current evidence suggests mixing COVID-19 vaccines is safe.*
 - ii. *There is a possibility of increased side effects that may last a few days such as fatigue, pain at the injection site, chills, headache, muscle pain, joint pain, and generally not feeling well. It may be more likely to have side effects with a shorter period of 4 weeks between the 2 doses.*
 - iii. *There is evidence that getting an mRNA vaccine as second dose after AstraZeneca/COVISHIELD will boost the immune response however there is limited data available.*
 - iv. *Studies on mixed COVID-19 vaccine brands or types are ongoing.*

**For clients who select AstraZeneca/COVISHIELD COVID-19 vaccine or are undecided:**

- b. *Please consider the following information in order to provide consent for your immunization today:*
- i. *This vaccine is approved for use in those 18 years of age and older by Health Canada.*
 - ii. *Current evidence suggests VITT occurs in about 1 in every 600,000 individuals following a second dose of AstraZeneca/COVISHIELD vaccine.*

3. *Would you like to continue with immunization today?*

Yes- continue to review applicable information sheet and screening questions with the client.

No- offer to answer additional questions and/or provide more information and close the conversation.
